r/rxrx

From my experience as a long-time stock investor..... Companies whose IR teams fail to communicate effectively with the outside world rarely have a bright future.

What everyone should be concerned about is the industry's reaction to the FDA's uncertainty. Although compelling Phase 2 data for the FAP treatment was reported, approaching the FDA seems like it will be difficult until 'the dust settles.' What on earth does 'the dust settling' even look like at this point? Will it be positive for Rec-4881?

A company where the Investor Relations team is just slacking off. A company that thinks taciturnity and silence are virtues. I wish they were even half as good as Insilico Medicine..

A company that doesn't even realize its stock price is tanking as a result.Look at that, insider selling just keeps continuing today without end.

upcoming June 30 clinical data release for REC-1245. Option traders are aggressively bidding up call options for late June because clinical trial outcomes are the ultimate binary "make-or-break" triggers for biotech stocks.
3. Near-Term "Max Pain" and Price Magnet
For the immediate weekly options chains, the market's "Max Pain" level (the strike price where the highest number of options expire worthless, acting as a short-term price magnet) has been hovering around the $3.50 to $4.50 range depending on the specific week.

Summary Verdict
The options chain confirms exactly what the institutional analysts are saying: the market is largely ignoring short-term daily fluctuations and treats RXRX as a coiled spring ahead of the late June clinical catalysts. The extreme 79% Call bias tells us that the options market is positioned for a major breakout if the data hits. End of June will be make or break

Nothing is going to save this company except forced take over.

Morgan Stanley raised the firm’s on Recursion Pharmaceuticals () to $5.50 from $5 and keeps an Equal Weight rating on the shares.
🚀🚀🚀

Institutional "Whale" Accumulation

While insiders are liquidating for taxes, the largest asset managers in the world are increasing their conviction:

• Vanguard Group: In their most recent filing update, Vanguard increased its position by +18.1%, now holding approximately 47.6 million shares.

• BlackRock: As noted earlier, BlackRock recently filed a 7.2% stake, signaling they are using the current $3.00–$3.50 price range to build a long-term position.

• Pictet Asset Management: Reported a massive +65.5% increase in their position this quarter, one of the most aggressive institutional "buy" signals in the TechBio sector. 

On May 7, 2026, analyst Gil Blum from Needham maintained a 'Buy' rating for Recursion Pharmaceuticals (RXRX). The price target remains unchanged at $8.00, reflecting the analyst's confidence in the company's performance.

• GF Value™ verdict: $5.12 vs Current Price $3.27 = 36.1% undervalued
• GF Score™: 75/100, indicating strong potential for long-term returns
• Key financial signal: Insider activity shows $1.4M in sales over the last 3 months

Source: https://www.gurufocus.com/news/8843812/rxrx-reiterates-by-needham-price-target-maintained-at-800